All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
New HIV prevention injection offers 96% protection
Last reviewed: 03.07.2025
A study by researchers at Emory University and Grady Health System found that a twice-yearly injection of Lenacapavir reduced the risk of HIV infection by 96%. These results make the drug more effective than traditional daily PrEP pills like Truvada®.
The results of the study were published in the New England Journal of Medicine.
Problems with Daily PrEP Medications
PrEP, including Truvada®, is effective in preventing HIV when taken daily. However, studies show that about 50% of patients stop taking it within the first year. Non-adherence reduces the effectiveness of treatment and compromises protection against infection.
Benefits of Lenacapavir
The Phase III clinical trial compared injectable Lenacapavir with daily Truvada®. The study included 2,179 people receiving Lenacapavir and 1,086 people receiving Truvada®.
- Only two people in the Lenacapavir group became infected with HIV, compared with nine cases in the Truvada® group.
- The efficacy of Lenacapavir was 96%.
- Compliance with treatment using injections was higher than in patients taking tablets.
Relevance for vulnerable groups
The trial included diverse groups, including cisgender men and gender non-binary people, at 88 sites in countries including Peru, Brazil, Mexico, South Africa, Thailand and the United States. It had a particular focus on racial and ethnic minorities, who are disproportionately affected by HIV.
- In 2022, more than half of new HIV cases in the United States were among gay cisgender men, of whom 70% were black or Hispanic.
Accessibility and the Future
Dr Colleen Kelly, lead author of the study, highlights the importance of Lenacapavir for those who have difficulty adhering to their pill regimen.
"For people who can't take daily medications, injectables will be a real breakthrough in helping them stay HIV negative," Kelly said.
Lenacapavir has already been submitted to the FDA for review and is expected to be approved by 2025.
Conclusion
Lenacapavir offers a revolutionary approach to HIV prevention, particularly for vulnerable populations. Successful integration of this drug into the healthcare system will significantly reduce the number of new HIV infections, while providing protection for those who cannot adhere to daily traditional medications.